XW033A7Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- Billable / Specific Code
XW033A7 is a billable ICD-10-PCS procedure code for Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 018. The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products. In AHRQ's Clinical Classifications Software (CCSR), this procedure falls under Chemotherapy.
Code Identity
PCS Table Breakdown
Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.
| Position | Designation | Value | Meaning |
|---|---|---|---|
| 1 | Section | X | New Technology |
| 2 | Body System | W | Anatomical Regions |
| 3 | Operation | 0 | Introduction |
| 4 | BodyPart | 3 | Peripheral Vein |
| 5 | Approach | 3 | Percutaneous |
| 6 | Device/Substance/Technology | A | Ciltacabtagene Autoleucel |
| 7 | Qualifier | 7 | New Technology Group 7 |
Clinical Classification (CCSR)
AHRQ groups XW033A7 into these clinical categories.
Code History
- XW033C3 — Introduce Auto CAR T cell in Periph Vein, Perc, New Tech 3
Similar Procedure Codes
Questions About XW033A7
Is XW033A7 a billable code?
Yes. XW033A7 is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7 on inpatient claims from October 1, 2025 through September 30, 2026.
What do the characters in XW033A7 mean?
XW033A7 breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 3 is the BodyPart (Peripheral Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character A is the Device/Substance/Technology (Ciltacabtagene Autoleucel); the 7th character 7 is the Qualifier (New Technology Group 7).
What MS-DRG does XW033A7 group to?
On an inpatient stay, Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7 maps to MS-DRG 018 (chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies). The MS-DRG sets the fixed Medicare payment for the stay.
